[Efficacy of mono- and polychemotherapy in patients with advanced ovarian cancer].
The effectiveness of mono- and polychemotherapy as components of combined treatment of 142 cases of stage IV ovarian cancer was evaluated. Remission was 1.3 times more frequent (85.7%) and its mean duration (10.8 months) was longer in patients who had received polychemotherapy than in cases of monochemotherapy, the respective figures in the latter group being 66.7% and 5.7 months. A 3-year survival and life-span were identical in both study groups. Poly- and monochemotherapy are equally effective in treatment of primary ovarian cancer.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011446:Prospective Studies; D011897:Random Allocation
D000970:Antineoplastic Agents
Ob éffektivnosti mono- i polikhimioterapii u bol'nykh rakom iaichnikov daleko zashedshikh stadiĭ.